OakChart

Sagimet Biosciences Inc

SGMTHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

11.41+0.52 (4.78%)
2026-11-12 06:33 CET
Market cap
809.07 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-47.08 USD m
Free cash flow, TTM
-41.72 USD m
EPS diluted, TTM
-1.28
P/E
-
Compare

Price

SGMT against its 20, 50 and 200-day averages
2050200beatmiss
6.008.0010.004.3M8.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SGMTclose 11.4120-day 9.8650-day 9.89200-day 7.6611.41

0.3% under the 52-week high of 11.45 on 10 Sep 2026. 52-week low 4.50 on 30 Mar 2026. Last 15 sessions, 26.8% high to low

Volume 1.41× normal · the line is the 50-bar volume average

Profile

SGMT
52-week range, 99% of the way up
4.5011.45

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

IndexRUT
Employees16
IPOJul 14, 2023
Beta3.41
ATR, 14d0.68
Rel volume1.41
Short float18.55%
Insider own7.47%
Inst own75.65%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap802.60M
Enterprise Value564.41M
Income-47.08M
Sales0.00M
Book/sh4.15
Cash/sh3.41
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees16
IPOJul 14, 2023

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.75
P/C3.34
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio44.94
Current Ratio44.94
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.28
EPS next Y-1.34
EPS next Q-0.26
EPS this Y28.71%
EPS next Y-19.27%
EPS next 5Y-0.08%
EPS past 3/5Y-3.41% -24.29%
Sales past 3/5Y- -
EPS Y/Y TTM30.54%
Sales Y/Y TTM-
EPS Q/Q18.57%
Sales Q/Q-
EarningsAug 11 BMO
EPS/Sales Surpr.-3.59% -

Ownership

Insider Own7.47%
Insider Trans-8.12%
Inst Own75.65%
Inst Trans108.21%
ROA-23.49%
ROE-24.37%
ROIC-18.25%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2015.77%
SMA5015.32%
SMA20049.01%
Trades-

Technical

Shs Outstand70.91M
Shs Float65.61M
Short Float18.55%
Short Ratio9.61
Short Interest12.17M
52W High11.45 -0.34%
52W Low4.50 153.56%
Volatility8.44% 7.21%
ATR (14)0.68
RSI (14)63.47
Beta3.41
Rel Volume1.41
Avg Volume1.27M
Volume1,790,319

Performance

Perf Week14.21%
Perf Month42.98%
Perf Quarter22.95%
Perf Half Y50.13%
Perf YTD92.74%
Perf Year34.24%
Perf 3Y341.39%
Perf 5Y-
Perf 10Y-
Recom1.36
Target Price27.92
Prev Close10.89
Price11.41
Change %4.78%

Analyst ratings

latest 10 of 18
DateActionAnalystRating changeTargetImplied
Sep 24, 2026ResumedGGoldmanSell$7-38.7%
Sep 09, 2026UpgradeBBarclaysEqual Weight → Overweight$18+57.8%
Sep 09, 2026InitiatedCCantor FitzgeraldOverweight
Mar 26, 2026InitiatedRRodman & RenshawBuy$28+145.4%
Feb 03, 2026InitiatedGGuggenheimBuy$27+136.6%
Jan 28, 2026InitiatedBBarclaysEqual Weight$8-29.9%
Aug 11, 2025InitiatedWWedbushOutperform$28+145.4%
Aug 07, 2025ResumedHH.C. WainwrightBuy$29+154.2%
Jul 24, 2025InitiatedCCanaccord GenuityBuy$28+145.4%
Dec 06, 2024InitiatedOOppenheimerOutperform$30+162.9%

Peers

Mkt cap
TickerCompanyMkt cap
MDGLMadrigal Pharmaceuticals Inc10.06B
IVAInventiva ADR958.79M
ALTAltimmune Inc375.41M
VKTXViking Therapeutics Inc3.63B
GALTGalectin Therapeutics Inc331.79M
SLGLSol-Gel Technologies Ltd207.57M
KLRAKailera Therapeutics Inc1.87B
LPCNLipocine Inc17.61M
NVONovo Nordisk ADR137.48B
GSKGSK Plc ADR101.43B

Insider trading

latest 14 of 16
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Kemble GeorgeDirectorAug 14 '26Option Exercise6.36350,9872,232,277413,148Aug 17 04:05 PM
Kemble GeorgeDirectorAug 14 '26Sale10.23350,9873,591,58062,161Aug 17 04:05 PM
GEORGE KEMBLEDirectorAug 14 '26Proposed Sale9.28350,9873,257,159Aug 14 04:34 PM
Kemble GeorgeDirectorAug 11 '26Option Exercise6.3620,206128,51082,367Aug 12 07:41 PM
Kemble GeorgeDirectorAug 11 '26Sale9.9520,206201,14762,161Aug 12 07:41 PM
GEORGE KEMBLEDirectorAug 11 '26Proposed Sale9.5720,206193,371Aug 11 04:30 PM
Happel DavidPresident & CEOJul 20 '26Sale7.7664,051497,068741,570Jul 22 04:05 PM
Rozek ElizabethChief Legal & Admin. OfficerJul 20 '26Sale7.7610,54581,832224,414Jul 22 04:05 PM
Kemble GeorgeDirectorJul 20 '26Sale7.4618,844140,52962,161Jul 22 04:05 PM
GEORGE KEMBLEDirectorJul 20 '26Proposed Sale7.8218,844147,360Jul 20 04:18 PM
Happel DavidPresident & CEOFeb 10 '26Sale5.3612,10164,865677,621Feb 12 04:08 PM
Chauche ThierryChief Financial OfficerFeb 10 '26Sale5.361,3127,03315,688Feb 12 04:07 PM
Martins Eduardo BrunoChief Medical OfficerFeb 10 '26Sale5.363,64019,511103,296Feb 12 04:06 PM
Rozek ElizabethChief Legal & Admin. OfficerFeb 10 '26Sale5.362,62214,054190,959Feb 12 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
DWASInvesco Dorsey Wright SmallCap Momentum ETFAUM: 391.13M

News

latest 14 of 200
  • Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne (GlobeNewswire)
  • Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference (GlobeNewswire)
  • Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.16%
  • Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data (InvestorsHub) +5.89%
  • Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial SGMT Stock Surges Pre-Market (Stocktwits)
  • Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants (GlobeNewswire)
  • Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 (GlobeNewswire)
  • Sagimet Biosciences to Host Virtual KOL Event, "Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US" on September 30, 2026 (GlobeNewswire) +7.58%
  • Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire)
  • Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 (GlobeNewswire)
  • Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Sagimet Biosciences Receives FDA "Study May Proceed" Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients (GlobeNewswire)
  • Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-11-0.260-0.251-0.2600.000.0011
2026Q12026-05-12-0.330-0.371-0.3270.000.0011
2025Q42026-03-11-0.290-0.432-0.2940.000.009
2025Q32025-11-13-0.400-0.386-0.3980.000.0010
2025Q22025-08-13-0.320-0.508-0.3230.000.0010
2025Q12025-05-08-0.560-0.666-0.5650.000.007
2024Q42025-03-12-0.500-0.621-0.5030.000.008
2024Q32024-11-14-0.450-0.388-0.4550.000.007
2024Q22024-08-14-0.250-0.332-0.2540.000.006
2024Q12024-05-15-0.230-0.387-0.2280.000.006
2023Q42024-03-25-0.383-0.578-0.3560.000.004
2023Q32023-11-13-0.350-1.028-0.2972.000.004
2023Q22023-08-21-35.800-0.498-0.3170.000.004
2023Q12023-08-07-0.430--0.3080.00--
2026Q3---0.260--0.0013
2026Q4---0.281--0.0012

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-2.660-37.275-1.2182.002.00
2024FY-1.450-1.568-1.4540.000.00
2025FY-1.580-1.664-1.5800.000.00
2026FY--1.127--0.00
2027FY--1.344--8.13
2028FY--1.584--24.16
2029FY--0.522--129.08
2030FY-0.806--310.28

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-2311000.000.000.00
2026Q3S2026-09-0810000.000.000.00
2026Q3S2026-08-119000.000.000.00
2026Q3S2026-05-259000.000.000.00
2026Q3S2026-05-129010.000.000.00
2026Q3S2026-04-249010.000.000.00
2026Q3S2026-03-118010.000.000.00
2026Q3S2026-02-114100.250.001.00
2026Q3S2026-02-055100.200.001.00
2026Q3S2026-02-024100.250.001.00
2026Q3S2025-11-134000.000.000.00
2026Q3S2025-11-123000.000.000.00
2026Q3S2025-11-113000.000.000.00
2026Q3S2025-11-103000.000.000.00

Estimate history

EPS, annual-0.667-0.532-1.144-1.427-1.218-1.454-1.578-1.2816
Period2019202020212022202320242025TTM
EPS, quarterly-0.254-0.455-0.503-0.565-0.323-0.398-0.294-0.327-0.263
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00002000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual21.37521.37521.37521.37522.89632.19532.52261.783
Period2019202020212022202320242025MRQ
Shares, quarterly31.91432.19532.19532.19532.19532.52232.52232.58561.783
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.002.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.00-0.130.130.120.09
Gross Profit0.000.000.00--0.13-0.13-0.12-0.09
Selling, General and Administrative Excl. Other52.6356.8954.4532.7430.9323.5911.2814.07
Research and Development34.9939.0538.4419.7824.9219.348.188.39
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-52.63-56.89-54.45-30.74-31.05-23.72-11.40-14.16
Interest Expense0.000.000.000.000.000.000.000.06
Unusual Expense0.000.000.00-0.00-0.000.750.000.17
Net Income Before Taxes-47.08-51.04-45.57-27.88-30.50-24.44-11.37-14.26
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-47.08-51.04-45.57-27.88-30.50-24.44-11.37-14.26
Net Income From Continuing Operations-47.08-51.04-45.57-27.88-30.50-24.44-11.37-14.26
Net Income-47.08-51.04-45.57-27.88-30.50-24.44-11.37-14.26
EPS (Recurring)-0.89-1.58-1.45-1.22-1.43-1.12-0.53-0.66
EPS (Basic, Before Extraordinaries)-1.28-1.58-1.45-1.22-1.43-1.14-0.53-0.67
EPS (Diluted)-1.28-1.58-1.45-1.22-1.43-1.14-0.53-0.67
EBITDA-52.63-56.89-54.45-30.74-30.93-23.59-11.28-14.07
Non-Operating Income (Expense)5.555.858.892.860.550.030.030.13
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.916.455.294.991.881.900.782.99
Price To Sales Ratio---62.05----
Operating Margin----1,537.00----
Net Margin----1,393.80----
Shares Outstanding61.7832.5232.2022.9021.3821.3821.3821.38
Market Capitalization809.07809.07144.88115.85115.85---

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other15.8211.7110.7714.3311.9319.8618.2016.90
Research and Development11.547.006.739.737.2515.3414.2212.65
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-15.82-11.71-10.77-14.33-11.93-19.86-18.20-16.90
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-13.95-10.65-9.57-12.91-10.39-18.18-16.20-14.62
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-13.95-10.65-9.57-12.91-10.39-18.18-16.20-14.62
Net Income From Continuing Operations-13.95-10.65-9.57-12.91-10.39-18.18-16.20-14.62
Net Income-13.95-10.65-9.57-12.91-10.39-18.18-16.20-14.62
EPS (Recurring)-0.26-0.33-0.29-0.40-0.32-0.56-0.50-0.45
EPS (Basic, Before Extraordinaries)-0.26-0.33-0.29-0.40-0.32-0.56-0.50-0.45
EPS (Diluted)-0.26-0.33-0.29-0.40-0.32-0.56-0.50-0.45
EBITDA-15.82-11.71-10.77-14.33-11.93-19.86-18.20-16.90
Non-Operating Income (Expense)1.861.061.201.431.541.691.992.28
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.691.841.691.691.601.471.531.55
Shares Outstanding61.7832.5932.5232.5232.2032.2032.2032.20
Market Capitalization809.07170.26192.53223.10245.33104.96144.8889.18

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments113.12151.2594.9032.3456.7368.7010.21
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets3.001.221.430.450.510.040.60
Total Current Assets116.12152.4796.3232.7957.2468.7410.81
Net Property, Plant & Equipment0.080.080.070.210.340.190.32
Total Investments and Advances0.007.410.000.000.000.000.00
Intangible Assets0.000.000.000.000.00--
Other Assets0.280.310.320.031.450.030.03
Total Assets116.48160.2696.7233.0359.0368.9611.16
Short Term Debt Incl. Current Port. of LT Debt0.080.080.070.130.120.140.13
Accounts Payable1.311.430.190.000.000.000.00
Other Current Liabilities3.712.955.405.152.321.761.95
Total Current Liabilities5.104.455.655.282.441.912.08
Long Term Debt0.000.000.000.080.220.070.21
Provision for Risks Charges0.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.010.010.01
Total Liabilities5.104.455.655.362.671.982.30
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.00214.62214.62202.88134.18
Common Equity111.38155.8191.06-186.95-158.26-135.91-125.31
Total Shareholders Equity111.38155.8191.0627.6756.3666.978.86
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity111.38155.8191.0627.6756.3666.978.86
Total Liabilities & Stockholders Equity116.48160.2696.7233.0359.0368.9611.16
Book Value Per Share3.424.843.98-8.75-7.40-6.36-5.86
Tangible Book Value Per Share3.424.843.98-8.75-7.40-6.36-5.86
Full-Time Employees16141010-55
Price to Book Ratio2.750.851.181.18---
Return on Assets-36.89-35.46-42.97-66.26-38.19-28.38-
Return on Equity-38.20-36.92-46.95-72.59-39.63-29.98-
Return on Invested Capital-45.82-29.25-30.61-109.91-43.20-16.96-157.15
Quick Ratio22.7634.2317.046.2123.4635.995.21
Current Ratio22.7634.2317.046.2123.4635.995.21

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-47.08-51.04-45.57-27.88-30.50-24.44-11.37-14.26
Depreciation----0.130.130.120.09
Other Funds (Non Cash)9.516.444.185.091.672.650.762.98
Funds from Operations-37.57-44.60-41.39-22.79-28.70-21.66-10.49-11.20
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-4.15-1.05-1.05-0.984.21-0.060.070.65
Cash from Operating Activities-41.72-45.65-42.44-23.77-24.49-21.71-10.42-10.55
Capital Expenditures0.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.020.00
Purchase or Sale of Investments0.634.56-61.6812.58-32.010.000.000.00
Purchase of Investments-94.98-106.86-108.09-19.62-41.450.000.000.00
Sale Or Maturity of Investments95.61111.4246.4032.209.440.000.000.00
Other Uses0.000.000.000.000.000.000.00-0.03
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities0.634.56-61.6812.58-32.010.000.02-0.03
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock164.570.28105.8689.690.0110.9968.8921.85
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock164.570.28105.8689.690.0110.9968.8921.85
Proceedsfrom Stock Options-10.800.00105.7589.680.0010.8068.8921.85
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.00-3.36
Change in Long Term Debt0.000.000.000.000.000.000.00-3.36
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00-3.36
Net Financing Active Other Cash Flow0.090.00-1.04-3.52-0.09-1.250.000.00
Other Financing Activities Uses0.000.00-1.04-3.52-0.09-1.250.000.00
Cash from Financing Activities164.660.28104.8286.17-0.079.7468.8918.48
Net Change in Cash123.57-40.820.7074.98-56.57-11.97--
Free Cash Flow-41.72-45.65-42.44-23.77-24.49-21.71-10.42-10.55
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments240.13104.54113.12116.69125.41144.57
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.432.773.002.541.170.88
Total Current Assets243.55107.31116.12119.23126.58145.45
Net Property, Plant & Equipment1.950.040.080.120.150.04
Total Investments and Advances17.440.000.008.8110.060.00
Intangible Assets-0.000.000.000.00-
Other Assets0.490.400.280.250.620.69
Total Assets263.43107.75116.48128.40137.41146.17
Short Term Debt Incl. Current Port. of LT Debt0.080.040.080.120.150.04
Accounts Payable1.132.301.314.241.923.22
Other Current Liabilities4.202.963.714.795.173.92
Total Current Liabilities5.425.305.109.157.257.18
Long Term Debt1.860.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities7.285.305.109.157.257.18
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity256.15102.46111.38119.25130.16138.99
Total Shareholders Equity256.15102.46111.38119.25130.16138.99
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity256.15102.46111.38119.25130.16138.99
Total Liabilities & Stockholders Equity263.43107.75116.48128.40137.41146.17
Book Value Per Share4.153.143.423.674.044.32
Tangible Book Value Per Share4.153.143.423.674.044.32
Full-Time Employees--16---
Price to Book Ratio2.751.531.611.701.770.67
Return on Assets-23.49-34.27-36.89-38.04-36.38-33.53
Return on Equity-24.37-36.04-38.20-39.78-37.89-34.72
Return on Invested Capital-5.41-10.39-8.59-10.82-7.98-13.08
Quick Ratio44.9420.2622.7613.0417.4720.26
Current Ratio44.9420.2622.7613.0417.4720.26

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-13.95-10.65-9.57-12.91-10.39-18.18
Other Funds (Non Cash)3.711.742.032.031.410.98
Funds from Operations-10.24-8.91-7.54-10.88-8.98-17.20
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.860.30-4.290.70-0.122.66
Cash from Operating Activities-11.10-8.61-11.83-10.18-9.10-14.54
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-24.0210.2214.360.07-13.293.41
Purchase of Investments-39.90-6.75-17.08-31.26-42.95-15.57
Sale Or Maturity of Investments15.8816.9731.4331.3429.6618.99
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-24.0210.2214.360.07-13.293.41
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock164.300.000.000.270.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock164.300.000.000.270.000.00
Proceedsfrom Stock Options-10.800.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.090.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities164.390.000.000.270.000.00
Net Change in Cash129.271.602.52-9.83-22.39-11.12
Free Cash Flow-11.10-8.61-11.83-10.18-9.10-14.54

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3018.55%12.2M65.6M1.34M
2026-10-1517.57%11.5M65.6M1.27M
2026-09-3017.06%11.2M65.6M1.21M
2026-09-1517.87%10.3M57.4M1.27M
2026-08-3117.61%10.1M57.4M1.20M
2026-08-1420.54%11.7M57.2M1.17M
2026-07-3120.02%11.6M57.9M1.05M
2026-07-1516.63%9.7M58.6M1.90M
2026-06-3014.09%8.3M58.6M1.76M
2026-06-159.95%5.8M58.6M1.47M
2026-05-298.20%4.8M58.6M1.43M
2026-05-157.19%4.2M58.6M1.37M
2026-04-308.75%4.5M51.8M1.35M
2026-04-1513.36%3.6M26.9M525.79K
2026-03-3111.98%3.2M26.9M576.73K
2026-03-1314.58%3.8M26.1M613.04K
2026-02-2714.03%3.7M26.1M651.42K
2026-02-1314.90%3.9M26.1M659.20K
2026-01-3012.94%3.4M26.3M601.22K
2026-01-1512.17%3.2M26.3M581.99K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.506.5010.108.2513.8644.000.000.988-0.0160.001
call5.004.508.403.7910.2944.000.000.966-0.0260.001
call7.501.504.803.104.11330.000.000.900-0.0450.003
call10.001.551.701.501.10441714.000.784-0.0370.005
call12.500.205.000.230.9635652650.300-0.0340.006
call15.000.000.100.061.2742371,0520.101-0.0230.003
call17.500.000.250.001.7660.000.000.078-0.0260.003
call20.000.000.150.002.1900.000.000.067-0.0280.002
call22.500.004.900.002.6010.000.000.060-0.0290.002
put2.500.004.900.005.2480.000.00-0.012-0.0160.001
put5.000.004.900.143.4081.000.00-0.034-0.0260.001
put7.500.000.250.202.4916200.00-0.100-0.0440.003
put10.000.100.300.151.2421,2277.00-0.216-0.0360.005
put12.501.251.451.951.0781.000.00-0.700-0.0330.006
put15.001.656.000.004.9840.000.00-0.899-0.0210.003
put17.504.007.500.004.2620.000.00-0.922-0.0240.003
put20.007.4011.000.006.2660.000.00-0.933-0.0260.002
put22.509.1013.500.006.7370.000.00-0.940-0.0280.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-228-KCurrent report2026-10-22SEC
2026-10-07SCHEDULE 13GSEC
2026-10-018-KCurrent report2026-09-30SEC
2026-10-01424B5SEC
2026-09-308-KCurrent report2026-09-30SEC
2026-09-30424B3SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-14144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13GSEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-30SCHEDULE 13GSEC
2026-07-224Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-07-224Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-07-224Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-07-218-KCurrent report2026-07-20SEC
2026-07-20144Filing for proposed sale of securities under Rule 144.SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-12SEC
2026-06-128-KCurrent report2026-06-12SEC
2026-06-038-KCurrent report2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-05-28SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08003.79M2
2026-0700719.43K3
2026-060000
2026-050000
2026-040000
2026-030000
2026-0200105.46K4
2026-010000
2025-120000
2025-1100289.98K1

Institutional holders

Manager% owned
BlackRock, Inc.10.65%
BALYASNY ASSET MANAGEMENT L.P.5.87%
Woodline Partners LP4.86%
SILVERARC CAPITAL MANAGEMENT, LLC4.74%
VANGUARD CAPITAL MANAGEMENT LLC4.16%
Caligan Partners LP4.05%
BVF INC/IL4.05%
Affinity Asset Advisors, LLC4.05%
FEDERATED HERMES, INC.3.38%
GREAT POINT PARTNERS LLC3.29%

Funds

Fund% owned
Federated Hermes Kaufmann Small Cap Fund3.37%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.01%
iShares Russell 2000 ETF2.43%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.59%
abrdn Life Sciences Investors1.37%
VANGUARD EXTENDED MARKET INDEX FUND1.07%
Fidelity Small Cap Index Fund1.04%
BlackRock Health Sciences Opportunities Portfolio0.94%
iShares Russell 2000 Growth ETF0.70%
iShares Biotechnology ETF0.67%

OakChart. SGMT. Cached 15 minutes.